- Conditions
- Colonic Polyps, Colon Cancer
- Interventions
- Peppermint Oil, Placebo
- Drug · Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 2,822
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- LY4088044, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Los Alamitos, California • Lenexa, Kansas • San Antonio, Texas + 1 more
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- glycine, placebo
- Drug · Other
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
- Conditions
- Healthy
- Interventions
- cangrelor, moxifloxacin, placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
- Interventions
- NKTR-118, moxifloxacin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
- Interventions
- MCS110, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- CTP-543, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Osteoarthritis, Knee
- Interventions
- Naproxen Sodium (Aleve, BAY117031), Acetaminophen ER, Celecoxib, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Pinellas Park, Florida • Chicago, Illinois + 2 more
- Conditions
- Hepatitis C Infection
- Interventions
- Daclatasvir, Placebo, Peginterferon alpha-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Neoplasms, Head and Neck
- Interventions
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Kansas City, Missouri • Charlotte, North Carolina
- Conditions
- Intestinal Failure Associated Liver Disease
- Interventions
- NST-6179 Part A, NST-6179 Part B, Matched Placebo
- Drug · Other
- Lead sponsor
- NorthSea Therapeutics B.V.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Bevacizumab [Avastin], Paclitaxel, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant
- Drug
- Lead sponsor
- Noema Pharma AG
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Drug Toxicity
- Interventions
- HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
- Interventions
- CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1292263, GSK1292263 matching placebo, Sitagliptin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
- Conditions
- Migraine
- Interventions
- TEZAMPANEL
- Drug
- Lead sponsor
- TorreyPines Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,415 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more
- Conditions
- Active Non-segmental Vitiligo
- Interventions
- PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
- Drug · Device
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 40
- States / cities
- Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
- Conditions
- High Blood Pressure, Flow Mediated Dilation
- Interventions
- fruit and vegetable juice supplement, Placebo
- Dietary Supplement
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Respiratory Compliance, Functional Residual Capacity, Pulmonary Function Testing
- Interventions
- betamethasone, placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetes Mellitus, Diabetic Nephropathy
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Interventions
- BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota